Crescent Biopharma Announces Grants of Inducement Awards
The employee’s options carry a $12.91 exercise price and vest over time, subject to continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crescent Biopharma (CBIO) announced inducement stock options covering 11,775 ordinary shares for one non-executive employee who accepted employment with the company. The Compensation Committee approved the award on November 2, 2026, under its amended 2025 Employment Inducement Incentive Award Plan.
The options have a $12.91 exercise price, matching the November 2 Nasdaq closing share price, and a 10-year term. One-fourth vests on the first anniversary of the employee’s start date, followed by one-forty-eighth monthly thereafter, subject to continuous service through each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.11,775 ordinary shares underlying employee options at a $12.91 exercise price represent potential dilution upon exercise.
Key Figures
- Options granted
- 11,775 options
- One non-executive employee
- Exercise price
- $12.91 per share
- Options approved November 2, 2026
- Option term
- 10 years
- Inducement options
- Vesting schedule
- One-fourth on the first anniversary; one-forty-eighth monthly thereafter
- Subject to continuous service through applicable vesting dates
Historical Context
-
Prior grant under the same plan covered 81,525 options for six employees, with a 10-year term.
-
Prior grant covered 31,200 shares for two employees, with a 10-year term and monthly vesting.
-
Prior grant covered 58,650 shares for two employees under the same inducement plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 11,775 shares of the Company’s ordinary shares to one non-executive employee as an equity inducement award under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on November 2, 2026 and were material to the employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Crescent Biopharma’s employee inducement options?
The award covers 11,775 ordinary shares at a $12.91 exercise price with a 10-year term. One-fourth vests on the first anniversary of the employee’s start date, with one-forty-eighth vesting monthly thereafter, subject to continuous service through the applicable vesting dates.